Search research articles
Contact Us
Filters
Showing results (61-70 of 74) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2019
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
R Condorelli, F Mosele, B Verret, et al.
ESMO Open
|
January 28, 2026
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer
K L Jhaveri, N M Iyengar, N C Turner, et al.
British Journal of Cancer
|
March 18, 2010
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
N C Turner, S J Strauss, D Sarker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2018
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
N C Turner, R S Finn, M Martin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2018
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
S A Hurvitz, R G W Quek, N C Turner, et al.
ESMO Open
|
August 31, 2024
Association of post-operative ctDNA detection with outcomes of patients with early breast cancers
R Cutts, L Ulrich, M Beaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
J Pascual, G Attard, F-C Bidard, et al.
ESMO Open
|
June 13, 2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
V Gambardella, M K Accordino, P L Bedard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2025
Whole genome sequencing-powered ctDNA sequencing for breast cancer detection
I Garcia-Murillas, C W Abbott, R J Cutts, et al.
ESMO Open
|
September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
H S Rugo, M Oliveira, S J Howell, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 74) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2019
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
R Condorelli, F Mosele, B Verret, et al.
ESMO Open
|
January 28, 2026
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer
K L Jhaveri, N M Iyengar, N C Turner, et al.
British Journal of Cancer
|
March 18, 2010
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
N C Turner, S J Strauss, D Sarker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2018
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
N C Turner, R S Finn, M Martin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2018
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
S A Hurvitz, R G W Quek, N C Turner, et al.
ESMO Open
|
August 31, 2024
Association of post-operative ctDNA detection with outcomes of patients with early breast cancers
R Cutts, L Ulrich, M Beaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
J Pascual, G Attard, F-C Bidard, et al.
ESMO Open
|
June 13, 2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
V Gambardella, M K Accordino, P L Bedard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2025
Whole genome sequencing-powered ctDNA sequencing for breast cancer detection
I Garcia-Murillas, C W Abbott, R J Cutts, et al.
ESMO Open
|
September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
H S Rugo, M Oliveira, S J Howell, et al.
Page
of 8